(0.37%) 5 118.73 points
(0.30%) 38 354 points
(0.35%) 15 983 points
(-0.74%) $83.23
(2.55%) $1.972
(0.08%) $2 349.00
(-0.07%) $27.52
(3.09%) $950.60
(-0.07%) $0.934
(-0.12%) $11.01
(-0.31%) $0.798
(1.51%) $93.26
Live Chart Being Loaded With Signals
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology...
Stats | |
---|---|
Dagens volum | 301 266 |
Gjennomsnittsvolum | 1.58M |
Markedsverdi | 45.60M |
EPS | $0 ( 2024-03-27 ) |
Neste inntjeningsdato | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.650 |
ATR14 | $0.00100 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-15 | Matkovits Theresa | Buy | 1 300 000 | Stock Option (right to Buy) |
2023-12-15 | Hoover Thomas | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Kucinski Keith A | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Liu Hui | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Jabbour Jerome D | Buy | 3 500 000 | Stock Option (right to Buy) |
INSIDER POWER |
---|
97.71 |
Last 97 transactions |
Buy: 33 257 124 | Sell: 4 123 116 |
Volum Korrelasjon
Matinas BioPharma Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Matinas BioPharma Korrelasjon - Valuta/Råvare
Matinas BioPharma Økonomi
Annual | 2023 |
Omsetning: | $1.10M |
Bruttogevinst: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2023 |
Omsetning: | $1.10M |
Bruttogevinst: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2022 |
Omsetning: | $3.19M |
Bruttogevinst: | $-13.49M (-423.15 %) |
EPS: | $-0.0600 |
FY | 2021 |
Omsetning: | $33.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Matinas BioPharma
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.